Study guide
9.3 Anticoagulation & ACT Targets
Registered Cardiovascular Invasive Specialist RCIS
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current RCIS Exam Facts 1.2 Eligibility Pathways & Documentation 1.3 Examination Matrix & Study Plan
2 Pre-Procedural Room Setup & Sterile Technique
2.1 Procedure & Control Room Setup 2.2 Sterile Technique & Universal Precautions 2.3 Personnel Preparation & Cath Lab Roles
3 Pre-Procedural Patient Preparation & Validation
3.1 Preparing the Patient for Invasive Procedures 3.2 Records, Labs, Allergies & Consent 3.3 Time-Out & Universal Protocol
4 Patient Monitoring & Vascular Access
4.1 Intraprocedural Vital Sign Monitoring 4.2 Arterial & Venous Access Sites 4.3 Ultrasound-Guided Access
5 Coronary Anatomy & Left Heart Catheterization
5.1 Coronary Anatomy & Dominance 5.2 Left Heart Catheterization & Coronary Angiography 5.3 Catheter Shapes & Angiographic Projections 5.4 Left Ventriculography & Aortography
6 Right Heart Catheterization & Hemodynamics
6.1 Right Heart Waveforms & Pressures 6.2 Cardiac Output: Fick & Thermodilution 6.3 Valve Area, Bernoulli & Shunt Calculations 6.4 Endomyocardial Biopsy Support
7 ECG & Intracardiac/Intravascular Imaging
7.1 12-Lead ECG in the Cath Lab 7.2 Intracardiac Echocardiography (ICE) 7.3 IVUS & OCT 7.4 Identifying Structures on Cardiac Ultrasound
8 Physiology Assessment & Radiation Safety
8.1 FFR & iFR Studies 8.2 Radiation Safety & ALARA 8.3 Radiographic Equipment Operation 8.4 Image Acquisition & Interpretation
9 Cath Lab Pharmacology
9.1 Anticipating Pharmacologic Needs 9.2 Recognizing Medication Effects & Adverse Reactions 9.3 Anticoagulation & ACT Targets
10 PCI Fundamentals
10.1 Balloon Angioplasty & Stent Platforms 10.2 Coronary Wiring, Lesion Prep & Flow Grades 10.3 Vascular Closure Devices
11 Chapter 11: Complex Coronary Intervention
11.1 CTO, Atherectomy & Alcohol Septal Ablation 11.2 Cardiac Thrombectomy (Mechanical & Aspiration) 11.3 Distal Protection Devices
12 Device Implants & Temporary Support
12.1 Pacemaker, ICD, CRT & Loop Recorders 12.2 Transvenous Temporary Pacemaker 12.3 Pericardiocentesis Support
13 Mechanical Circulatory Support
13.1 IABP & Impella 13.2 ECMO & LVAD Overview for the Cath Lab
14 Peripheral Vascular Interventions
14.1 Peripheral Interventions 14.2 Complex Peripheral Interventions 14.3 Peripheral Thrombectomy & Thrombolysis
15 Structural Heart Interventions
15.1 Nonvalvular Structural Therapies 15.2 Percutaneous Valve Interventions
16 Chapter 16: Emergency Clinical Presentations & Equipment
16.1 STEMI, Cardiogenic Shock & Pulmonary Edema 16.2 Stroke & Neurologic Emergencies in the Lab 16.3 Emergency Equipment Operation
17 Intraprocedural Complications
17.1 Coronary Interventional Complications 17.2 Peripheral & Structural Complications
18 Post-Procedural Activities
18.1 Arterial & Venous Hemostasis 18.2 Access-Site Complications 18.3 Patient Education, Reporting & Transfer of Care
9.3 Anticoagulation & ACT Targets
Key Takeaways Explain This Topic AI
ACT monitors unfractionated heparin effect in real time; commonly cited targets are ~200–250 sec diagnostic, ~250–300 sec PCI with GP IIb/IIIa, and ~300+ sec PCI without GP IIb/IIIa
PCI heparin is typically weight-based 70–100 U/kg IV bolus with repeat ACT checks and supplemental boluses if subtherapeutic
Bivalirudin is the standard non-heparin procedural anticoagulant for HIT patients and is not reversed with protamine
P2Y12 loading (clopidogrel, prasugrel, or ticagrelor) plus aspirin prevents stent thrombosis—ACT does not measure platelet inhibition
Femoral sheath removal generally requires ACT near 150–180 seconds or adequate time since last heparin; protamine 1 mg per 100 units UFH partially reverses heparin
Last updated: July 2026
9.3 Anticoagulation & ACT Targets
Quick Answer: Activated clotting time (ACT) guides unfractionated heparin (UFH) anticoagulation in the cath lab. Commonly cited targets: ~200–250 sec for diagnostic catheterization, ~250–300 sec for PCI with GP IIb/IIIa , and ~300+ sec for PCI without GP IIb/IIIa . Know heparin dosing , bivalirudin alternatives, P2Y12 loading, ACT monitoring , and reversal principles.
Anticoagulation prevents intracardiac and intracoronary thrombus during catheters, guidewires, and stent deployment—but excess anticoagulation drives access-site bleeding , retroperitoneal hemorrhage , and stroke from uncontrolled hypertension after sheath pull. RCIS candidates must fluently translate procedure type + anticoagulant choice → ACT goal → monitoring interval → closure criteria .
What ACT Measures
The activated clotting time (ACT) is a bedside whole-blood clotting assay (celite or kaolin activator) reporting seconds until clot formation. It is the primary monitor for UFH effect in the cath lab because it returns results in 2–3 minutes —fast enough to adjust boluses during PCI.
- Parameter Clinical meaning
- Baseline ACT Often ~100–120 sec (institution-specific) before heparin
- Subtherapeutic ACT during PCI ↑ risk of thrombus , acute stent thrombosis , stroke on catheters
- Supratherapeutic ACT ↑ bleeding , hematoma , tamponade risk (especially femoral)
- Testing frequency After bolus , after additional doses , q15–30 min during long PCI, before sheath removal
Always record activator type (celite vs kaolin)—values are not interchangeable between methods.
Diagnostic vs Interventional ACT Targets
These ranges appear throughout CCI prep materials and ACC/AHA/SCAI practice patterns. Institutional protocols may vary slightly —follow your lab's written standard—but exam items use the commonly cited numbers:
Procedure context Typical UFH approach Commonly cited ACT target
Diagnostic coronary angiography 2,000–5,000 units IV after access or ~50 U/kg ; radial protocols often anticoagulate to reduce RAO ~200–250 sec
- PCI with planned GP IIb/IIIa inhibitor 70–100 U/kg IV bolus (max per protocol) ~250–300 sec
- PCI without GP IIb/IIIa 70–100 U/kg IV bolus ~300–350 sec (often simplified as 300+ sec )
Structural / post-transseptal LA work Heparin after successful puncture (timing varies) >250 sec , often 250–350 sec
Sheath removal (femoral manual compression) N/A—reversal/metabolism ACT ~150–180 sec or per protocol before pull
Exam shorthand many candidates memorize:
- Diagnostic: 200–250
- PCI + IIb/IIIa: 250–300
- PCI without IIb/IIIa: 300+
If ACT is below target mid-PCI, anticipate additional UFH bolus per physician order and repeat ACT —never assume one bolus lasts the entire case.
Heparin Dosing and Monitoring Workflow
Confirm no HIT history and no active major bleeding .
Administer bolus (weight-based for PCI).
Draw ACT 3–5 minutes after bolus (allows circulation).
Document time, dose, ACT, and repeat per protocol.
Communicate sub/supratherapeutic values to the operator before continuing high-risk steps (stent deployment, prolonged equipment in LV).
- ACT result Typical team response (operator-directed)
- Below PCI target Additional UFH bolus (e.g., 2,000–5,000 units) and repeat ACT
Above target with active bleeding Hold further anticoagulation; consider protamine ; vascular/surgical consult if major bleed
Therapeutic range Proceed; continue periodic ACT checks
Low-molecular-weight heparin (LMWH) is not monitored with ACT and is not the standard procedural anticoagulant for PCI in most US cath labs—do not confuse exam distractors.
Bivalirudin (Direct Thrombin Inhibitor)
Bivalirudin is a recombinant hirudin analog with predictable anticoagulation , short half-life , and no protamine reversal .
- Feature UFH Bivalirudin
- Primary monitor ACT ACT (partially) + time from dose
- HIT patients Contraindicated Preferred alternative
- Bleeding vs heparin + IIb/IIIa Higher with IIb/IIIa combo Lower bleeding in many STEMI/NSTEMI PCI trials
- Reversal Protamine None specific —supportive; clears with renal metabolism
- Typical PCI dosing Weight-based bolus 0.75 mg/kg bolus then 1.75 mg/kg/h infusion (verify current protocol)
RCIS items may ask which agent to anticipate when platelets crashed after recent heparin and HIT is suspected —answer bivalirudin (or argatroban ), and stop all heparin including line flushes.
GP IIb/IIIa Inhibitors (Context for ACT)
Abciximab, eptifibatide, tirofiban block final common pathway of platelet aggregation. Routine use has declined with potent P2Y12 inhibitors and improved stent platforms, but CCI still tests ACT interaction :
With IIb/IIIa , lower ACT target (250–300) because dual pathway blockade ↑ bleeding if ACT is pushed to 350+.
Recognize thrombocytopenia and mucosal bleeding as class effects.
P2Y12 Inhibitors and Dual Antiplatelet Therapy (DAPT)
P2Y12 agents (clopidogrel, prasugrel, ticagrelor) are antiplatelet , not anticoagulants— ACT does not measure their effect . They are essential for stent thrombosis prevention and appear in anticoagulation cross-cut RCIS items.
- Agent Loading (typical adult PCI context) Onset notes RCIS pearls
- Clopidogrel 300–600 mg loading Slower onset Verify CYP2C19 issues in some protocols
- Prasugrel 60 mg loading Faster; potent Contraindicated prior stroke/TIA history
- Ticagrelor 180 mg loading Fast; reversible Dyspnea side effect; BID maintenance
Aspirin (162–325 mg loading, then 81 mg daily) remains foundation of DAPT. Confirm loading occurred before or during PCI when stenting is planned.
Cross-cut exam trap: A question about ACT 280 sec may still require recognizing inadequate platelet inhibition if no P2Y12 load was given—anticoagulation alone does not prevent stent thrombosis .
ACT at Case End: Sheath Removal and Reversal
After femoral PCI, ACT must fall before manual compression or closure device deployment:
Many protocols: ACT <150–180 sec or ≥4–6 h since last heparin if ACT unavailable.
Protamine 1 mg per 100 units UFH in prior hour (max ~50 mg) partially reverses UFH; give slowly —risk hypotension , bradycardia , pulmonary hypertension .
Radial access often permits early ambulation with patent hemostasis —still document ACT if protocol requires before transfer.
- Situation RCIS consideration
- ACT still 290 at scheduled femoral pull Delay pull , notify operator, repeat ACT, consider protamine per order
- Bleeding with therapeutic ACT Manual pressure , reverse anticoagulation , type & cross , surgical backup
Bivalirudin case ending No protamine; rely on discontinuation + time ; follow radial/femoral hemostasis protocol
Special Populations
- Population Anticoagulation note
- Renal failure Bivalirudin clearance ↓—may need dose adjustment; bleeding risk ↑
- Obesity Weight-based heparin—use actual body weight unless protocol caps
- HIT / thrombocytopenia No UFH ; use bivalirudin/argatroban ; platelet monitoring
- Prior intracranial hemorrhage Operator weighs bleeding vs ischemia—may alter ACT goals
Quick Reference: Anticoagulation Decision Tree Procedure planned?
- ├── Diagnostic cath → UFH (often 2–5k U or 50 U/kg) → ACT ~200–250
- ├── PCI ± IIb/IIIa
- │ ├── IIb/IIIa YES → UFH 70–100 U/kg → ACT ~250–300
- │ └── IIb/IIIa NO → UFH 70–100 U/kg → ACT ~300+
- ├── HIT suspected/confirmed → Bivalirudin (no heparin)
- └── Stent placed → Confirm aspirin + P2Y12 load (ACT does not assess DAPT)
- RCIS Documentation Checklist
- Heparin dose , time , route , weight used for calculation
- ACT values with activator type and clock time
- P2Y12 agent, dose , time (and aspirin)
- Bivalirudin bolus/infusion rates if used
- Protamine dose/time if given
- ACT prior to sheath removal or hemostasis device deployment
Mastering ACT targets links Domain B diagnostic pharmacology with interventional anticoagulation —the cross-cut CCI uses to see whether you can keep a patient therapeutically anticoagulated during stenting and safely hemostatic afterward .